22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › ROYALTY PHARMA PLC › 2024-2025

ROYALTY PHARMA PLC 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ROYALTY PHARMA PLC’s Form 8-K, filed May 12, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 24Reported items
  • 429Asset managers, any item
  • 10,926Fund votes
  • May 12, 2025Meeting date

Results at a glance

Meeting of May 12, 2025: 23 items on ROYALTY PHARMA PLC’s Form 8-K, filed May 12, 2025: 23 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ROYALTY PHARMA PLC in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ROYALTY PHARMA PLC

These tallies are ROYALTY PHARMA PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ROYALTY PHARMA PLC — official shareholder meeting results, meeting held May 12, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
1. To authorize the chairman, if he determines that there are insufficient votes cast in favor of the Internalization Proposal, to adjourn the Annual Meeting to such time and place (which place may include electronic platforms) that he, in his absolute discret 429,870,97910,759,799119,406 --52,966,444 98%Passed (calculated)—
2. To approve (a) the Membership Interest Purchase Agreement and each other transaction document, (b) grant allotment authority for the issuance of (i) additional Class A ordinary shares of the Company sufficient to allow for the exchange of a number of Class 440,522,94874,301152,935 --52,966,444 99.9%Passed (calculated)—
3. To approve, on a non-binding advisory basis, the compensation that may become payable to the Company's named executive officers in connection with the Transaction 420,544,94420,056,306148,934 --52,966,444 95%Passed (calculated)—
4. To adopt the 2025 Equity Incentive Plan 421,957,43218,098,447694,305 --52,966,444 96%Passed (calculated)—
5. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares 427,171,59812,769,237809,349 --52,966,444 97%Passed (calculated)—
Elect Director: Pablo Legorreta 418,582,71022,097,92869,546 --52,966,444 95%Passed (calculated)—
Elect Director: Henry Fernandez 436,765,4093,917,78966,986 --52,966,444 99.1%Passed (calculated)—
Elect Director: Bonnie Bassler, Ph.D. 435,725,0564,959,62165,507 --52,966,444 99%Passed (calculated)—
Elect Director: Vlad Coric, M.D. 438,209,7982,473,99866,388 --52,966,444 99.4%Passed (calculated)—
Elect Director: Errol De Souza, Ph.D. 431,649,2029,034,00066,982 --52,966,444 98%Passed (calculated)—
Elect Director: Catherine Engelbert 437,305,9293,379,45164,804 --52,966,444 99.2%Passed (calculated)—
Elect Director: David Hodgson 430,015,00210,669,26965,913 --52,966,444 98%Passed (calculated)—
Elect Director: Ted Love, M.D. 408,610,51831,393,111746,555 --52,966,444 93%Passed (calculated)—
Elect Director: Gregory Norden 429,848,85810,832,65768,669 --52,966,444 98%Passed (calculated)—
7. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers 403,157,46536,842,162750,557 --52,966,444 92%Passed (calculated)—
8. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm 493,521,988116,39678,244 ---- 99.9%Passed (calculated)—
9. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports, including the directors' report, the strategic report, the directors' remuneration report and the auditors' report for the fiscal year ended Dece 493,059,16698,388559,074 ---- 99.9%Passed (calculated)—
10. To approve, the Company's U.K. directors' remuneration policy, included in U.K. directors' remuneration report contained in the U.K. Annual Report and Accounts 398,711,62241,343,662694,900 --52,966,444 91%Passed (calculated)—
11. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts 400,460,68540,156,539132,960 --52,966,444 91%Passed (calculated)—
12. To re-appoint Ernst & Young Chartered Accountants as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are pr 493,516,330112,51287,786 ---- 99.9%Passed (calculated)—
13. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor 439,898,126775,67176,387 --52,966,444 99.8%Passed (calculated)—
14. To authorize the Board of Directors to allot shares 422,290,98817,779,779679,417 --52,966,444 96%Passed (calculated)—
15. To authorize the Board of Directors to allot shares without rights of pre-emption 406,273,29733,785,707691,180 --52,966,444 92%Passed (calculated)—

Source: ROYALTY PHARMA PLC, Form 8-K, filed with the SEC on May 12, 2025 — read the filing on EDGAR.

How asset managers voted at the ROYALTY PHARMA PLC 2024-2025 meeting

429 asset managers disclosed a vote on at least one ROYALTY PHARMA PLC item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ROYALTY PHARMA PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Bonnie Bassler, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 435,725,056AGAINST: 4,959,621

Prior year: 98.8% for (June 6, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: Election of Directors: Bonnie Bassler, Ph.D.

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Bonnie Bassler, Ph.D.”): 435,725,056 for, 4,959,621 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 122,745,886 for, 926,653 against, 40,943 abstained, 151 not voted.

FOR
FOR: 122,745,886AGAINST: 926,653ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “Election of Directors: Bonnie Bassler, Ph.D.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5354 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional0757,205 00Against
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

Elect Director: Catherine Engelbert

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 437,305,929AGAINST: 3,379,451

Prior year: 99.2% for (June 6, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: Election of Directors: Catherine Engelbert

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Catherine Engelbert”): 437,305,929 for, 3,379,451 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 123,610,552 for, 61,987 against, 40,943 abstained, 151 not voted.

FOR
FOR: 123,610,552AGAINST: 61,987ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “Election of Directors: Catherine Engelbert” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5363 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

Elect Director: David Hodgson

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 430,015,002AGAINST: 10,669,269

Prior year: 97.6% for (June 6, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: Election of Directors: David Hodgson

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: David Hodgson”): 430,015,002 for, 10,669,269 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 122,724,925 for, 947,614 against, 40,943 abstained, 151 not voted.

FOR
FOR: 122,724,925AGAINST: 947,614ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “Election of Directors: David Hodgson” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5318 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional0757,205 00Against
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

Elect Director: Errol De Souza, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 431,649,202AGAINST: 9,034,000

Prior year: 96.3% for (June 6, 2024 meeting) ▲ 1.6 pts

Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: Election of Directors: Errol De Souza, Ph.D.

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Errol De Souza, Ph.D.”): 431,649,202 for, 9,034,000 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 122,720,949 for, 951,590 against, 40,943 abstained, 151 not voted.

FOR
FOR: 122,720,949AGAINST: 951,590ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “Election of Directors: Errol De Souza, Ph.D.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5308 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI774,1763,976 00For
Dimensional0757,205 00Against
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

Elect Director: Gregory Norden

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 429,848,858AGAINST: 10,832,657

Prior year: 97.3% for (June 6, 2024 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: Election of Directors: Gregory Norden

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Gregory Norden”): 429,848,858 for, 10,832,657 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 122,725,020 for, 947,520 against, 40,943 abstained, 151 not voted.

FOR
FOR: 122,725,020AGAINST: 947,520ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “Election of Directors: Gregory Norden” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5309 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI774,1763,976 00For
Dimensional0757,205 00Against
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

Elect Director: Henry Fernandez

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 436,765,409AGAINST: 3,917,789

Prior year: 96.2% for (June 6, 2024 meeting) ▲ 2.9 pts

Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: Election of Directors: Henry Fernandez

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Henry Fernandez”): 436,765,409 for, 3,917,789 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 123,631,510 for, 41,030 against, 40,943 abstained, 151 not voted.

FOR
FOR: 123,631,510AGAINST: 41,030ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “Election of Directors: Henry Fernandez” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5363 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

Elect Director: Pablo Legorreta

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 418,582,710AGAINST: 22,097,928

Prior year: 96.6% for (June 6, 2024 meeting) ▼ 1.6 pts

Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: Election of Directors: Pablo Legorreta

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Pablo Legorreta”): 418,582,710 for, 22,097,928 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 123,473,517 for, 199,023 against, 40,943 abstained, 151 not voted.

FOR
FOR: 123,473,517AGAINST: 199,023ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “Election of Directors: Pablo Legorreta” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5309 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional697,31959,886 00Mixed
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

Elect Director: Ted Love, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 408,610,518AGAINST: 31,393,111

Prior year: 94.1% for (June 6, 2024 meeting) ▼ 1.3 pts

Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: Election of Directors: Ted Love, M.D.

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Ted Love, M.D.”): 408,610,518 for, 31,393,111 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 120,401,365 for, 3,173,553 against, 138,565 abstained, 151 not voted.

FOR
FOR: 120,401,365AGAINST: 3,173,553ABSTAIN: 138,565NOT VOTED: 151
Largest asset managers voting on “Election of Directors: Ted Love, M.D.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,887,6726,866 10For
Fidelity36,506,2730 00For
Morgan Stanley10,454,3017,009 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed0799,720 00Against
MUTUAL FUND SERIES TRUST785,4230 00For
SEI0778,152 00Against
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments0706,504 00Against
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

Elect Director: Vlad Coric, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 438,209,798AGAINST: 2,473,998
Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: Election of Directors: Vlad Coric, M.D.

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Vlad Coric, M.D.”): 438,209,798 for, 2,473,998 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 123,672,538 for, 1 against, 40,943 abstained, 151 not voted.

FOR
FOR: 123,672,538AGAINST: 1ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “Election of Directors: Vlad Coric, M.D.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5381 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A…

Calculated outcomeEXTRAORDINARY TRANSACTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 427,171,598AGAINST: 12,769,237
Details: description as filed, official tally, votes by 95 asset managers

Description as filed by funds: APPROVE THE TERMS OF THE AGREEMENTS AND COUNTERPARTIES PURSUANT TO WHICH WE MAY PURCHASE OUR CLASS A ORDINARY SHARES.

ROYALTY PHARMA PLC’s own tally for this item (“5. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares”): 427,171,598 for, 12,769,237 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 123,652,749 for, 1 against, 1 abstained, 151 not voted.

FOR
FOR: 123,652,749AGAINST: 1ABSTAIN: 1NOT VOTED: 151
Largest asset managers voting on “APPROVE THE TERMS OF THE AGREEMENTS AND COUNTERPARTIES PURSUANT TO WHICH WE MAY PURCHASE OUR CLASS A ORDINARY ” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5371 10For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 95 asset managers. All 95 are in the interactive database (link above).

To approve (a) the Membership Interest Purchase Agreement and each other transaction document, (b) grant allotment…

Calculated outcomeCAPITAL STRUCTUREPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 440,522,948AGAINST: 74,301
Details: description as filed, official tally, votes by 95 asset managers

Description as filed by funds: APPROVE (A) THE MEMBERSHIP INTEREST PURCHASE AGREEMENT AND EACH OTHER TRANSACTION DOCUMENT, (B) GRANT ALLOTMENT AUTHORITY FOR THE ISSUANCE OF (I) ADDITIONAL CLASS A ORDINARY SHARES OF ROYALTY PHARMA PLC SUFFICIENT TO ALLOW FOR THE EXCHANGE OF A NUMBER OF CLASS B ORDINARY SHARES OF ROYALTY PHARMA HOLDINGS LTD. EQUAL TO THE SHARE CONSIDERATION AND (II) ADDITIONAL CLASS B ORDINARY SHARES OF ROYALTY PHARMA PLC EQUAL TO THE SHARE CONSIDERATION, AND (C) ADOPT AMENDED ARTICLES OF ASSOCIATION OF ROYALTY PHARMA PLC (SPECIAL RESOLUTION).

ROYALTY PHARMA PLC’s own tally for this item (“2. To approve (a) the Membership Interest Purchase Agreement and each other transaction document, (b) grant allotment authority for the issuance of (i) additional Class A ordinary shares of the Company sufficient to allo”): 440,522,948 for, 74,301 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 123,652,750 for, 0 against, 0 abstained, 151 not voted.

FOR
FOR: 123,652,750AGAINST: 0ABSTAIN: 0NOT VOTED: 151
Largest asset managers voting on “APPROVE (A) THE MEMBERSHIP INTEREST PURCHASE AGREEMENT AND EACH OTHER TRANSACTION DOCUMENT, (B) GRANT ALLOTMEN” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5390 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 95 asset managers. All 95 are in the interactive database (link above).

To authorize the Board of Directors to allot shares without rights of pre-emption

Calculated outcomeSHAREHOLDER RIGHTS AND DEFENSESPassed (calculated)

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 406,273,297AGAINST: 33,785,707
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: AUTHORIZE THE BOARD TO ALLOT SHARES WITHOUT RIGHTS OF PRE-EMPTION (SPECIAL RESOLUTION).

ROYALTY PHARMA PLC’s own tally for this item (“15. To authorize the Board of Directors to allot shares without rights of pre-emption”): 406,273,297 for, 33,785,707 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of ROYALTY PHARMA PLC’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Authorize Issue of Equity without Pre-emptive Rights” (2 managers, 61,374 for).

The 94 asset managers below reported 122,047,520 for, 1,604,587 against, 1 abstained, 151 not voted.

FOR
FOR: 122,047,520AGAINST: 1,604,587ABSTAIN: 1NOT VOTED: 151
Largest asset managers voting on “AUTHORIZE THE BOARD TO ALLOT SHARES WITHOUT RIGHTS OF PRE-EMPTION (SPECIAL RESOLUTION).” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard35,609,0771,285,461 10For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

Authorize the board to allot shares.

No official matchCAPITAL STRUCTURE

Combines 2 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 94 asset managers

Description as filed by funds: AUTHORIZE THE BOARD TO ALLOT SHARES.

The 94 asset managers below reported 123,587,913 for, 64,194 against, 1 abstained, 151 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 123,587,913AGAINST: 64,194ABSTAIN: 1NOT VOTED: 151
Largest asset managers voting on “AUTHORIZE THE BOARD TO ALLOT SHARES.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5335 10For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

To authorize the chairman, if he determines that there are insufficient votes cast in favor of the Internalization…

Calculated outcomeOTHERPassed (calculated)

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 429,870,979AGAINST: 10,759,799
Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: DIRECT THE CHAIRMAN, IF HE DETERMINES THAT THERE ARE INSUFFICIENT VOTES CAST IN FAVOR OF PROPOSAL 2 (BELOW), TO ADJOURN THE ANNUAL GENERAL MEETING AND SPECIAL MEETING TO SUCH TIME AND PLACE THAT HE, IN HIS ABSOLUTE DISCRETION, CONSIDERS FIT.

ROYALTY PHARMA PLC’s own tally for this item (“1. To authorize the chairman, if he determines that there are insufficient votes cast in favor of the Internalization Proposal, to adjourn the Annual Meeting to such time and place (which place may include electronic pla”): 429,870,979 for, 10,759,799 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 123,333,196 for, 339,343 against, 40,943 abstained, 151 not voted.

FOR
FOR: 123,333,196AGAINST: 339,343ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “DIRECT THE CHAIRMAN, IF HE DETERMINES THAT THERE ARE INSUFFICIENT VOTES CAST IN FAVOR OF PROPOSAL 2 (BELOW), T” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,52810 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

To adopt the 2025 Equity Incentive Plan

Calculated outcomeFund totals may overlapCOMPENSATIONPassed (calculated)

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 421,957,432AGAINST: 18,098,447
Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: APPROVE THE ADOPTION THE 2025 EQUITY INCENTIVE PLAN.

ROYALTY PHARMA PLC’s own tally for this item (“4. To adopt the 2025 Equity Incentive Plan”): 421,957,432 for, 18,098,447 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 94 asset managers voting on “APPROVE THE ADOPTION THE 2025 EQUITY INCENTIVE PLAN.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5335 10For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Fund voting reports, all 94 managers: 123,576,176 for, 75,932 against, 1 abstained, 151 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 4 asset managers voting on “APPROVE THE ADOPTION THE 2025 EQUITY INCENTIVE PLAN.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Caledonia (Private) Investments Pty Ltd4,436,0800 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC6420 00For
Boltwood Capital Management1000 00For
VOISARD ASSET MANAGEMENT GROUP, INC.170 00For

Institutional-manager reports, all 4 managers: 4,436,839 for.

To approve, on a non-binding advisory basis, the compensation that may become payable to the Company's named executive…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 420,544,944AGAINST: 20,056,306
Details: description as filed, official tally, votes by 423 asset managers

Description as filed by funds: A non-binding advisory vote to approve executive compensation that may become payable in connection with the transaction contemplated by the Membership Interest Purchase Agreement.

ROYALTY PHARMA PLC’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation that may become payable to the Company's named executive officers in connection with the Transaction”): 420,544,944 for, 20,056,306 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 95 asset managers voting on “A non-binding advisory vote to approve executive compensation that may become payable in connection with the t” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5327 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,950,3359,164 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Fund voting reports, all 95 managers: 123,430,129 for, 227,236 against, 40,943 abstained, 151 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 356 asset managers voting on “A non-binding advisory vote to approve executive compensation that may become payable in connection with the t” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Morgan Stanley32,083,5580 00For
Fidelity31,504,9700 00For
Swedbank Robur Fonder AB012,157,470 00Against
BlackRock11,161,402524,825 00For
VIKING GLOBAL INVESTORS LP9,005,9240 00For
GEODE CAPITAL MANAGEMENT, LLC8,037,8570 00For
State Street7,094,8190 00For
Caledonia (Private) Investments Pty Ltd4,436,0800 00For
BAILLIE GIFFORD & CO LTD3,736,5250 00For
Victory Capital3,700,9120 00For
BAILLIE GIFFORD OVERSEAS LTD3,337,8230 00For
Charles Schwab3,164,4880 00For
Capital Group2,934,4530 00For
BAILLIE GIFFORD & CO2,773,5810 00For
NEW SOUTH CAPITAL MANAGEMENT INC2,661,0540 00For
GMT CAPITAL CORP2,335,4270 00For
Northern Trust2,277,7600 00For
Legal & General Investment Management Ltd104,5362,057,839 00Against
HOMESTEAD ADVISERS CORP1,939,4400 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC1,830,6480 00For
London LGPS CIV Ltd1,820,1820 00For
Vanguard1,784,9280 00For
JUPITER ASSET MANAGEMENT LTD1,695,4930 00For
Two Sigma1,656,7790 00For
HSBC1,629,7100 00For

Institutional-manager reports, all 356 managers: 180,026,559 for, 19,048,711 against, 2,360 withheld, 47,216 abstained, 15,398 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Non-binding advisory vote to approve executive compensation.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

89% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 418 asset managers

Description as filed by funds: A non-binding advisory vote to approve executive compensation.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 95 asset managers voting on “A non-binding advisory vote to approve executive compensation.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,879,38315,156 10For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI0778,152 00Against
Dimensional0757,205 00Against
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments0706,504 00Against
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Fund voting reports, all 95 managers: 120,504,012 for, 3,153,353 against, 40,944 abstained, 151 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 351 asset managers voting on “A non-binding advisory vote to approve executive compensation.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Morgan Stanley32,083,5580 00For
Fidelity31,504,9700 00For
Swedbank Robur Fonder AB012,157,470 00Against
BlackRock11,684,9481,279 00For
VIKING GLOBAL INVESTORS LP9,005,9240 00For
GEODE CAPITAL MANAGEMENT, LLC8,037,8570 00For
State Street7,094,8190 00For
Caledonia (Private) Investments Pty Ltd4,436,0800 00For
BAILLIE GIFFORD & CO LTD3,736,5250 00For
Victory Capital3,700,9120 00For
BAILLIE GIFFORD OVERSEAS LTD3,337,8230 00For
Charles Schwab3,164,4880 00For
Capital Group2,934,4530 00For
BAILLIE GIFFORD & CO2,773,5810 00For
NEW SOUTH CAPITAL MANAGEMENT INC2,661,0540 00For
GMT CAPITAL CORP02,335,427 00Against
Northern Trust2,277,7600 00For
Legal & General Investment Management Ltd2,156,0616,314 00For
HOMESTEAD ADVISERS CORP1,939,4400 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC1,830,6480 00For
London LGPS CIV Ltd1,820,1820 00For
Vanguard1,784,9280 00For
JUPITER ASSET MANAGEMENT LTD1,695,4930 00For
Two Sigma1,656,7790 00For
HSBC01,629,710 00Against

Institutional-manager reports, all 351 managers: 167,709,492 for, 31,347,190 against, 2,360 withheld, 56,716 abstained, 15,398 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containing the…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 6 wordings of this item as funds reported it.

95% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 117 asset managers

Description as filed by funds: Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containing the directors' remuneration policy) for the fiscal year ended December 31, 2024.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 94 asset managers voting on “Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containin” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,879,37915,160 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab7753,108,692 00Against
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI0778,152 00Against
Dimensional0757,205 00Against
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments0706,504 00Against
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Fund voting reports, all 94 managers: 117,448,909 for, 6,162,256 against, 40,943 abstained, 151 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 24 asset managers voting on “Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containin” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock11,684,9481,279 00For
Caledonia (Private) Investments Pty Ltd4,436,0800 00For
WEDGE CAPITAL MANAGEMENT L L P/NC30,845625,497 00Against
Portolan Capital Management, LLC420,4520 00For
Treasurer of the State of North Carolina0306,234 00Against
First Trust12,9300 00For
ADVISOR PARTNERS II, LLC10,6740 00For
Evercore Wealth Management, LLC5,1780 00For
Vident Advisory, LLC4,4240 00For
FINANCIAL CONSULATE, INC04,000 00Against
Savant Capital, LLC02,395 00Against
TIEDEMANN ADVISORS, LLC2,3090 00For
NATIONAL BANK TRUST INC.1,5760 00For
MERCER GLOBAL ADVISORS INC /ADV1,4640 00For
EVERGREEN CAPITAL MANAGEMENT LLC8950 00For
Chicago Partners Investment Group LLC8410 00For
Lee Financial Co0627 00Against
NORRIS PERNE & FRENCH LLP/MI5000 00For
Scott & Selber, Inc.2000 00For
Glenview Trust Co1190 00For
Boltwood Capital Management1000 00For
WESTWOOD HOLDINGS GROUP INC240 00For
Haverford Trust Co018 00Against
WRAPMANAGER INC06 00Against

Institutional-manager reports, all 24 managers: 16,613,559 for, 940,056 against.

Approve on a binding basis our u.k. directors' remuneration policy.

Combines 3 wordings of this item as funds reported it.

96% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 98 asset managers

Description as filed by funds: APPROVE ON A BINDING BASIS OUR U.K. DIRECTORS' REMUNERATION POLICY.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 94 asset managers voting on “APPROVE ON A BINDING BASIS OUR U.K. DIRECTORS' REMUNERATION POLICY.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,879,37715,161 10For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab7753,108,692 00Against
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI0778,152 00Against
Dimensional0757,205 00Against
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments0706,504 00Against
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Fund voting reports, all 94 managers: 117,448,907 for, 6,162,258 against, 40,944 abstained, 151 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 4 asset managers voting on “APPROVE ON A BINDING BASIS OUR U.K. DIRECTORS' REMUNERATION POLICY.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock11,684,9481,279 00For
Caledonia (Private) Investments Pty Ltd4,436,0800 00For
Janney Montgomery Scott LLC05,890 00Against
Boltwood Capital Management1000 00For

Institutional-manager reports, all 4 managers: 16,121,128 for, 7,169 against.

To approve, the Company's U.K. directors' remuneration policy, included in U.K. directors' remuneration report…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 398,711,622AGAINST: 41,343,662
Details: description as filed, official tally, votes by 7 asset managers

Description as filed by funds: APPROVE REMUNERATION POLICY

ROYALTY PHARMA PLC’s own tally for this item (“10. To approve, the Company's U.K. directors' remuneration policy, included in U.K. directors' remuneration report contained in the U.K. Annual Report and Accounts”): 398,711,622 for, 41,343,662 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 2 asset managers voting on “APPROVE REMUNERATION POLICY” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
AGF Investments Trust46,2000 00For
GuideStone15,1740 00For

Fund voting reports, all 2 managers: 61,374 for.

Institutional-manager reports: 5 asset managers voting on “APPROVE REMUNERATION POLICY” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock1,008,4810 00For
Regime de rentes du Mouvement Desjardins067,647 00Against
Uniplan Investment Counsel, Inc.12,1810 00For
LOUISBOURG INVESTMENTS INC.0905 00Against
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma0364 00Against

Institutional-manager reports, all 5 managers: 1,020,662 for, 68,916 against.

To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 439,898,126AGAINST: 775,671
Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: AUTHORIZE THE BOARD TO DETERMINE THE REMUNERATION OF ERNST & YOUNG IN ITS CAPACITY AS OUR U.K. STATUTORY AUDITOR.

ROYALTY PHARMA PLC’s own tally for this item (“13. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor”): 439,898,126 for, 775,671 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 123,672,638 for, 1 against, 40,943 abstained, 151 not voted.

FOR
FOR: 123,672,638AGAINST: 1ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “AUTHORIZE THE BOARD TO DETERMINE THE REMUNERATION OF ERNST & YOUNG IN ITS CAPACITY AS OUR U.K. STATUTORY AUDIT” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5381 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 98 asset managers. All 98 are in the interactive database (link above).

To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 493,521,988AGAINST: 116,396

Prior year: 100.0% for (June 6, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 97 asset managers

Description as filed by funds: RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.

ROYALTY PHARMA PLC’s own tally for this item (“8. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm”): 493,521,988 for, 116,396 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 97 asset managers below reported 123,672,556 for, 0 against, 40,943 abstained, 151 not voted.

FOR
FOR: 123,672,556AGAINST: 0ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5390 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 97 asset managers. All 97 are in the interactive database (link above).

To re-appoint Ernst & Young Chartered Accountants as the Company's U.K. statutory auditor under the U.K. Companies Act…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 493,516,330AGAINST: 112,512
Details: description as filed, official tally, votes by 96 asset managers

Description as filed by funds: RE-APPOINT ERNST & YOUNG AS OUR U.K. STATUTORY AUDITOR, TO HOLD OFFICE UNTIL THE CONCLUSION OF THE NEXT GENERAL MEETING AT WHICH THE U.K. ANNUAL REPORT AND ACCOUNTS ARE PRESENTED TO SHAREHOLDERS.

ROYALTY PHARMA PLC’s own tally for this item (“12. To re-appoint Ernst & Young Chartered Accountants as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which th”): 493,516,330 for, 112,512 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 96 asset managers below reported 123,672,539 for, 0 against, 40,943 abstained, 151 not voted.

FOR
FOR: 123,672,539AGAINST: 0ABSTAIN: 40,943NOT VOTED: 151
Largest asset managers voting on “RE-APPOINT ERNST & YOUNG AS OUR U.K. STATUTORY AUDITOR, TO HOLD OFFICE UNTIL THE CONCLUSION OF THE NEXT GENERA” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5390 00For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).

To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 493,059,166AGAINST: 98,388
Details: description as filed, official tally, votes by 95 asset managers

Description as filed by funds: APPROVE RECEIPT OF OUR U.K. AUDITED ANNUAL REPORT AND ACCOUNTS AND RELATED DIRECTORS' AND AUDITOR'S REPORTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024.

ROYALTY PHARMA PLC’s own tally for this item (“9. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports, including the directors' report, the strategic report, the directors' remuneration report and the auditor”): 493,059,166 for, 98,388 against, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 123,611,182 for, 17 against, 40,944 abstained, 151 not voted.

FOR
FOR: 123,611,182AGAINST: 17ABSTAIN: 40,944NOT VOTED: 151
Largest asset managers voting on “APPROVE RECEIPT OF OUR U.K. AUDITED ANNUAL REPORT AND ACCOUNTS AND RELATED DIRECTORS' AND AUDITOR'S REPORTS FO” at ROYALTY PHARMA PLC, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard36,894,5380 10For
Fidelity36,506,2730 00For
Morgan Stanley10,461,3100 00For
BlackRock6,959,4990 00For
Victory Capital6,381,1790 00For
Charles Schwab3,109,4670 00For
Transamerica2,430,2090 00For
Advisor Managed Portfolios2,270,0000 00For
Capital Group1,912,4550 00For
Brighthouse1,761,3360 00For
First Trust1,013,4860 00For
TIAA837,3900 00For
Waddell & Reed799,7200 00For
MUTUAL FUND SERIES TRUST785,4230 00For
SEI778,1520 00For
Dimensional757,2050 00For
INVESTMENT CO OF AMERICA746,5480 00For
Russell Investments706,5040 00For
Pacific Life597,8260 00For
AQR589,5210 00For
Invesco492,2620 00For
HOMESTEAD FUNDS INC483,4840 00For
Thrivent464,3810 00For
JPMorgan451,9210 00For
AB EQUITY INCOME FUND INC365,6720 00For

Showing the 25 largest of 95 asset managers. All 95 are in the interactive database (link above).

Largest ROYALTY PHARMA PLC shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 435,480,000 shares outstanding at the time of that meeting.

Fund voting reports: top ROYALTY PHARMA PLC shareholders by shares voted on “AUTHORIZE THE BOARD TO DETERMINE THE REMUNERATION OF ERNST & YOUNG IN ITS CAPACITY AS OUR U.K…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 8.47%
2Fidelity 8.38%
3Morgan Stanley 2.40%
4BlackRock 1.60%
5Victory Capital 1.47%
6Charles Schwab 0.71%
7Transamerica 0.56%
8Advisor Managed Portfolios 0.52%
9Capital Group 0.44%
10Brighthouse 0.40%
Institutional-manager reports: top ROYALTY PHARMA PLC shareholders by shares voted on “A non-binding advisory vote to approve executive compensation that may become payable in…”, 2024-2025
#Asset manager % of shares outstanding
1Morgan Stanley 7.37%
2Fidelity 7.23%
3Swedbank Robur Fonder AB 2.79%
4BlackRock 2.68%
5VIKING GLOBAL INVESTORS LP 2.07%
6GEODE CAPITAL MANAGEMENT, LLC 1.85%
7State Street 1.63%
8Caledonia (Private) Investments Pty Ltd 1.02%
9BAILLIE GIFFORD & CO LTD 0.86%
10Victory Capital 0.85%

Reported ROYALTY PHARMA PLC holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ROYALTY PHARMA PLC holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Legorreta G. Pablo103,112,796 —Schedule 13D, filed May 23, 2025
RPI US Partners 2019, LP98,287,272 —Proxy statement (DEF 14A), proxy filed April 10, 2026
FMR (Fidelity)39,404,093 —Form 13F, quarter ended March 31, 2025
Morgan Stanley38,907,011 —Proxy statement (DEF 14A), proxy filed April 10, 2026
Vanguard Group36,677,448 —Form 13F, quarter ended March 31, 2025
Capital International Investors32,745,526 —Proxy statement (DEF 14A), proxy filed April 10, 2026
FMR LLC27,900,714 —Proxy statement (DEF 14A), proxy filed April 10, 2026
BlackRock24,555,862 —Form 13F, quarter ended March 31, 2025
R & H Trust Co. (Guernsey) Limited24,223,082 —Schedule 13D, filed February 20, 2026
General Atlantic, L.P.14,243,870 —Schedule 13G, filed August 14, 2025

Percentages above are of 435,480,000 shares outstanding, as reported by ROYALTY PHARMA PLC on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ROYALTY PHARMA PLC's shareholder meeting held May 12, 2025, in the 2024-2025 proxy season, 429 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 10,926 separate fund positions. Their filings are grouped here into 24 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — A non-binding advisory vote to approve executive compensation that may become payable in… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ROYALTY PHARMA PLC's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 12, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ROYALTY PHARMA PLC’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ROYALTY PHARMA PLC proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “ROYALTY PHARMA (RPRX) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/royalty-pharma-plc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.